Daré Bioscience Secures $2M NIH Grant and Launches Phase 2 HPV Trial
DARE•Daré Bioscience received the second $1.0 million tranche of its $2.0 million NIAID grant for DARE-HPV, bolstering non-dilutive funding for the program. The Phase 2 trial has been initiated in approximately 100 women with persistent high-risk HPV, with topline safety and antiviral data expected in 2027.
1. NIH Funding Milestone
Daré Bioscience received the second $1.0 million tranche of a NIAID SBIR grant, bringing total NIH funding for DARE-HPV to $2.0 million for non-clinical development from December 2024 through November 2026.
2. Phase 2 Trial Initiation
The Phase 2 trial is a randomized, placebo-controlled, double-blind study evaluating DARE-HPV’s safety and antiviral activity in approximately 100 women with persistent high-risk HPV infection over a 21-day dosing period.
3. Funding Strategy and Pipeline Impact
The program is also supported by an up to $10 million ARPA-H contract, underscoring Daré’s strategy of leveraging non-dilutive government funding to advance its women’s health pipeline without diluting shareholders.
4. Market Need and Future Outlook
With no FDA-approved pharmacologic treatments for high-risk HPV, DARE-HPV could address an unmet market of six million U.S. women annually, with topline data expected in 2027 as a key catalyst.
Related News
Sources
Dare Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Finviz
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Globenewswire
